Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NVO

Novo Nordisk ADR

Mar 24 • 04:00PM ET

75.33

Dollar change -1.53
Percentage change -1.99	%

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Peers: LLY PFE MRK ABBV BMY JNJ AMGN REGN GILD VRTX

| Held by: AVDE PPH NUGO DFIC APIE PID RVER OZEM DFAI DFAX

Scroll to Statements

Index	-	P/E	22.95	EPS (ttm)	3.28	Insider Own	0.01%	Shs Outstand	3.37B	Perf Week	-6.01%
Market Cap	253.42B	Forward P/E	15.65	EPS next Y	4.81	Insider Trans	0.00%	Shs Float	3.36B	Perf Month	-14.48%
Income	14.65B	PEG	1.15	EPS next Q	0.89	Inst Own	10.12%	Short Float	0.40%	Perf Quarter	-28.91%
Sales	42.09B	P/S	6.02	EPS this Y	23.02%	Inst Trans	0.32%	Short Ratio	1.60	Perf Half Y	-44.15%
Book/sh	4.49	P/B	16.79	EPS next Y	23.75%	ROA	26.33%	Short Interest	13.51M	Perf Year	-42.21%
Cash/sh	1.09	P/C	69.37	EPS next 5Y	20.04%	ROE	82.03%	52W Range	73.80 - 148.15	Perf YTD	-12.43%
Dividend Est.	1.94 (2.57%)	P/FCF	23.68	EPS past 5Y	21.74%	ROI	45.25%	52W High	-49.15%	Beta	0.56
Dividend TTM	0.52 (0.69%)	Quick Ratio	0.55	Sales past 5Y	18.58%	Gross Margin	84.67%	52W Low	2.07%	ATR (14)	2.87
Dividend Ex-Date	Mar 31, 2025	Current Ratio	0.74	EPS Y/Y TTM	21.42%	Oper. Margin	44.94%	RSI (14)	36.65	Volatility	2.07% 2.39%
Employees	76302	Debt/Eq	0.72	Sales Y/Y TTM	24.91%	Profit Margin	34.81%	Recom	1.88	Target Price	115.99
Option/Short	Yes / Yes	LT Debt/Eq	0.62	EPS Q/Q	28.11%	Payout	34.97%	Rel Volume	0.92	Prev Close	76.86
Sales Surprise	7.50%	EPS Surprise	6.56%	Sales Q/Q	29.02%	Earnings	Feb 05 BMO	Avg Volume	8.45M	Price	75.33
SMA20	-9.20%	SMA50	-9.72%	SMA200	-32.99%	Trades		Volume	7,736,142	Change	-1.99%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Upgrade	Kepler	Hold → Buy
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Jan-06-25	Upgrade	Bernstein	Underperform → Mkt Perform
May-30-24	Initiated	Goldman	Buy	$156
Apr-12-24	Initiated	BMO Capital Markets	Outperform	$163
Jan-23-24	Initiated	Morgan Stanley	Overweight	$120
Jan-16-24	Resumed	UBS	Neutral
Dec-01-23	Initiated	Cantor Fitzgerald	Overweight	$120
Oct-02-23	Initiated	Argus	Buy	$110
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-15-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-28-22	Downgrade	UBS	Neutral → Sell
Jun-27-22	Upgrade	Exane BNP Paribas	Underperform → Neutral
Jun-07-22	Upgrade	JP Morgan	Neutral → Overweight
May-31-22	Upgrade	Guggenheim	Neutral → Buy
Apr-25-22	Upgrade	Cowen	Market Perform → Outperform	$130
Apr-12-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Mar-16-22	Upgrade	Deutsche Bank	Hold → Buy
Jan-25-22	Downgrade	Liberum	Hold → Sell

Show Previous Ratings

Today 04:17PM	Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble. (Investor's Business Daily)
02:50PM	BlackRock International Fund Q4 2024 Commentary (SeekingAlpha)
01:45PM	Novo Nordisk A/S Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights NVO (GlobeNewswire)
01:14PM	Wegovy Just Got a Massive Price Cut -- Novo's Bold Strike in the Obesity Drug War (GuruFocus.com)
12:44PM	Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped (Motley Fool)
12:30PM	Loading…
12:30PM	Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients (Quartz)
12:19PM	Novo Nordisk's $2 billion obesity deal (CNBC TV)
11:50AM	Ariel International Fund And Ariel Global Fund Q4 2024 Commentary (SeekingAlpha)
11:05AM	Novo Nordisk Down 15% in March: Is This a Buying Opportunity? (Zacks)
10:37AM	Novo Nordisk Is Licensing a Chinese Weight-Loss Drug. Why the Stock Is Down. (Barrons.com)
10:15AM	Ariel International And Global Funds Q4 2024 Commentary (SeekingAlpha)
10:15AM	Ariel International And Global Fudns Q4 2024 Commentary (SeekingAlpha)
09:25AM	Novo Nordisk Strikes $2B Deal for Obesity Drug (Investopedia)
08:43AM	Novo Nordisk to Pay Up to $2 Billion for Chinese Weight-Loss Drug License, Stock Drops (Barrons.com)
08:02AM	Novo adds to obesity drug pipeline via $200M deal with China-based biotech (BioPharma Dive)
08:00AM	Loading…
08:00AM	Novo Nordisk expands Wegovy $499-per-month offering to additional cash-paying patients via the Wegovy savings offer (PR Newswire)
07:27AM	5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes (Zacks)
06:21AM	Novo licenses Chinese biotech's obesity drug candidate for up to $2 billion (Reuters)
06:03AM	SAP Topples Novo to Become Europes Biggest Listed Company (Bloomberg)
06:02AM	The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist (GlobeNewswire)
05:20AM	Software maker SAP unseats Novo Nordisk as Europe's largest company (Reuters)
Mar-23-25 07:19AM	AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market (MarketBeat)
04:43AM	Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly (Motley Fool)
Mar-22-25 06:52PM	Novo Nordisk (NVO): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil (Insider Monkey)
Mar-21-25 12:05PM	The Davenport Core Leaders Fund Q4 2024 Commentary (SeekingAlpha)
11:17AM	Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell? (Investor's Business Daily)
10:17AM	Eli Lilly launches weight-loss drug Mounjaro in India, Reuters says (TipRanks)
08:30AM	Artisan International Small-Mid Fund Q4 2024 Commentary (SeekingAlpha)
07:21AM	Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy (SeekingAlpha)
05:45AM	Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO (PR Newswire)
05:45PM	Loading…
Mar-20-25 05:45PM	Why Novo Nordisk (NVO) Dipped More Than Broader Market Today (Zacks)
04:59PM	Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment (SeekingAlpha)
01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha)
11:15AM	Lazard International Strategic Equity Portfolio Q4 2024 Commentary (SeekingAlpha)
10:32AM	GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold? (Zacks)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
08:20AM	Eli Lilly launches weight loss drug in India beating Novo Nordisk (SeekingAlpha)
07:00AM	Invesco Global Fund Q4 2024 Commentary (SeekingAlpha)
06:59AM	OptiNose climbs after take-private deal with Paratek Pharma (SeekingAlpha)
06:40AM	Invesco Global Focus Fund Q4 2024 Commentary (SeekingAlpha)
05:35AM	Lazard International Equity Select Portfolio Q4 2024 Commentary (SeekingAlpha)
05:15AM	Lazard International Equity Portfolio Q4 2024 Commentary (SeekingAlpha)
02:54AM	Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market (Reuters)
Mar-19-25 09:21PM	BlackRock Global Dividend Fund Q4 2024 Commentary (SeekingAlpha)
09:47AM	Novo Nordisk A/S (NVO) Traded Lower Due To Investor Disappointment Over Its New Drug In Obesity (Insider Monkey)
09:30AM	Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
09:19AM	Is This Simple Index Fund a Millionaire Maker? (Fool)
09:09AM	Novo Nordisk A/S (NVO) Dropped as Trial Results Fell Short of Expectations (Insider Monkey)
08:29AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
06:00AM	Consumer sector is a 'better barometer' than Nvidia (Yahoo Finance Video)
Mar-18-25 06:05PM	Novo Nordisk (NVO) to be Market Leader Despite Horrifying Declines (Insider Monkey)
05:30PM	UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension (Benzinga)
04:47PM	Why Novo Nordisk Stock Outpaced the Market on Tuesday (Motley Fool)
01:45PM	Novo Nordisk (NVO): Among the Best Diabetes Stocks to Buy According to Billionaires (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 44.2% Upside in Novo Nordisk (NVO): Here's What You Should Know (Zacks)
09:40AM	Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term (Zacks)
08:45AM	Is Viking Therapeutics the Next Blockbuster GLP-1 Stock? (MarketBeat)
05:45AM	Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO (PR Newswire)
Mar-17-25 01:21PM	The cost of GLP-1s needs to come way down for benefits to be worth it, study says (Quartz)
11:26AM	Novo Nordisk Stock Rises Ahead of Data on Ozempic Ingredient's Ability to Lower Heart Risk (Investopedia)
09:30AM	Why Novo Nordisk (NVO) is a Top Stock for the Long-Term (Zacks)
09:00AM	Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock (Zacks)
06:47AM	3 Unstoppable Stocks You Can Buy Now Without Any Hesitation (Motley Fool)
05:00AM	The weight loss drug shortage is over and some patients are 'panicking' (Quartz)
Mar-14-25 06:08PM	Drugmakers agree to participate in second round of price negotiations (Reuters)
05:00AM	An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup (Quartz)
Mar-13-25 05:45PM	Novo Nordisk (NVO) Gains As Market Dips: What You Should Know (Zacks)
12:35PM	Wall Street's Biggest Novo Nordisk Bear Just Flipped--Here's Why He Says It's Time to Buy (GuruFocus.com)
10:32AM	UiPath plunges on weak outlook, Novo Nordisk upgrade: Top Stocks (Yahoo Finance Video)
09:28AM	Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak (Bloomberg)
Mar-12-25 07:26PM	Novo Nordisk sell-off is completely overdone, says Mizuho's Jared Holz (CNBC TV)
04:09PM	Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion (Investor's Business Daily)
04:03PM	Roche, Zealand sign deal: What it means for weight loss drug space (Yahoo Finance Video)
02:23PM	Novo Nordisk Is Falling. Competition Is a Killer. (Barrons.com)
12:48PM	Novo Nordisk, Starbucks shares slumping: Trending Tickers (Yahoo Finance Video)
12:12PM	Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on the Way. (Barrons.com)
12:10PM	iRobot, Target, Novo Nordisk vs. Roche: Market Minute (Yahoo Finance Video)
12:08PM	Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped (Motley Fool)
12:02PM	Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4% (Yahoo Finance)
12:02PM	Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4% (Yahoo Finance)
11:56AM	Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal (The Wall Street Journal)
10:09AM	Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly (Investopedia)
09:47AM	Novo Nordisk Stock Falls After Roche Strikes Weight-Loss Deal (The Wall Street Journal)
08:53AM	Novo Nordisk, Lilly Stocks Are Falling. A Rival Weight-Loss Drug Is on the Way. (Barrons.com)
07:26AM	NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target (Investing.com)
Mar-11-25 04:58PM	Viking strikes $150m deal to secure supply of obesity drug (Pharmaceutical Technology)
10:05AM	Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes (TipRanks)
09:51AM	H.C. Wainwright says Novo results support Viking obesity potential (TipRanks)
09:16AM	Novo Nordisk Shares Drop After CagriSema Trial Data Falls Short of Expectations (GuruFocus.com)
08:35AM	Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial (Benzinga)
04:10AM	Is Eli Lilly Stock a Buy? (Motley Fool)
Mar-10-25 09:00PM	Ozempics New Frontier: The War on Aging (The Wall Street Journal) -9.43%
06:54PM	Why Eli Lilly Stock Flopped Today (Motley Fool)
04:31PM	Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand. (Investor's Business Daily)
02:31PM	Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says (Quartz)
01:52PM	Novo Nordisk Shares Tumble 8% on CagriSema Weight Loss Miss (GuruFocus.com)
12:55PM	The State of Weight Loss Drugs (Motley Fool)
12:14PM	Novo Nordisks stock drops despite CagriSema hitting goal of Phase III trial (Clinical Trials Arena)
11:44AM	Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints (The Wall Street Journal)
11:42AM	Stocks to Watch Monday: Apple, Tesla, Robinhood, Google (The Wall Street Journal)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience